We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Hikma Pharmaceuticals plc (PK) | USOTC:HKMPY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 50.66 | 48.97 | 52.56 | 7 | 15:41:07 |
From Jun 2019 to Jun 2024
By Adria Calatayud
Hikma Pharmaceuticals PLC said Thursday that talks have ceased over a potential acquisition of GlaxoSmithKline PLC's pharmaceutical and consumer businesses in Egypt and pharmaceutical business in Tunisia.
FTSE 100 pharmaceutical company Hikma said it won't be launching a mandatory tender offer process to acquire shares in GlaxoSmithKline SAE Egypt.
Hikma in January said that it had entered into a preliminary agreement with GSK's Egyptian subsidiary.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
March 11, 2021 09:02 ET (14:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals (PK) Chart |
1 Month Hikma Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
